US · VTVT · BIOTECHNOLOGY
vTv Therapeutics Inc. (VTVT) intrinsic value and stock valuation
$15.51as of 2026-11-21 · Mkt cap 90.01M
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
vTv Therapeutics Inc. DCF and intrinsic value
InvestorsCraft values VTVT with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from VTVT’s statements →
vTv Therapeutics Inc. Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2013–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.00 | $1.02M | $0.00 | $2.02M | $4M |
| Operating income | -$-32.81M | -$-24.18M | -$-25.5M | -$-22.54M | -$-21.66M |
| Net income | -$-26.97M | -$-18.46M | -$-20.25M | -$-19.16M | -$-12.99M |
| EPSd | -$-3.2M | -$-3.2M | -$-9.74M | -$-9.98M | -$-8.27M |
| Operating cash flow | -$-25.25M | -$-25.31M | -$-19.08M | -$-15.25M | -$-19.31M |
| Capital expenditure | $0.00 | $0.00 | $0.00 | -$-20K | $0.00 |
| Free cash flow | -$-25.25M | -$-25.31M | -$-19.08M | -$-15.27M | -$-19.31M |
| Total assets | $89.9M | $38.3M | $11M | $33.2M | $25.5M |
| Total debt | $0.00 | $170K | $530K | $720K | $930K |
| Net debt | -$-88.93M | -$-36.58M | -$-8.92M | -$-11.41M | -$-12.48M |
| Total equity | $64.4M | $14.3M | -$-18.55M | $5.84M | $15.2M |
| Cash and short-term investments | $88.9M | $36.8M | $9.45M | $12.1M | $13.4M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.00 | $1.02M | $0.00 | $2.02M | $4M |
| Cost of revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $1.02M | $0.00 | $2.02M | $4M |
| Research and development expenses | $17.9M | $11.6M | $13.6M | $12.4M | $13.3M |
| Selling, general and administrative expenses | $15M | $13.7M | $11.9M | $12.2M | $12.3M |
| Other expenses | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating expenses | $32.8M | $25.2M | $25.5M | $24.6M | $25.7M |
| Cost and expenses | $32.8M | $25.2M | $25.5M | $24.6M | $25.7M |
| Interest income | $1.87M | $1.56M | $470K | $350K | $0.00 |
| Interest expense | $10K | $0.00 | $10K | $10K | $10K |
| Depreciation and amortization | $20K | $90K | $90K | $90K | $90K |
| Ebitda | -$-31.06M | -$-22.52M | -$-25.86M | -$-24.77M | -$-17.52M |
| Operating income | -$-32.81M | -$-24.18M | -$-25.5M | -$-22.54M | -$-21.66M |
| Total other income/expenses, net | $1.73M | $1.57M | -$-460K | -$-2.33M | $4.05M |
| Income before tax | -$-31.08M | -$-22.61M | -$-25.97M | -$-24.87M | -$-17.62M |
| Income tax expense | $0.00 | $100K | $0.00 | $200K | $120K |
| Net income | -$-26.97M | -$-18.46M | -$-20.25M | -$-19.16M | -$-12.99M |
| Weighted average shares outstanding | $8.42M | $5.77M | $2.08M | $1.92M | $1.57M |
| Weighted average diluted shares outstanding | $8.42M | $5.77M | $2.08M | $1.92M | $1.57M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $88.9M | $36.8M | $9.45M | $12.1M | $13.4M |
| Net receivables | $0.00 | $60K | $100K | $12.4M | $60K |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 | $100K |
| Total current assets | $89.9M | $38.1M | $10.7M | $27.1M | $15.6M |
| Property, plant and equipment, net | $0.00 | $150K | $360K | $560K | $680K |
| Goodwill and intangible assets | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Long-term investments | $0.00 | $0.00 | $0.00 | $5.59M | $9.17M |
| Total non-current assets | $10K | $150K | $360K | $6.14M | $9.85M |
| Total assets | $89.9M | $38.3M | $11M | $33.2M | $25.5M |
| Accounts payable | $1.13M | $940K | $4.08M | $2.46M | $1.88M |
| Short-term debt | $0.00 | $170K | $360K | $380K | $440K |
| Deferred revenue | $0.00 | $0.00 | $20K | $20K | $40K |
| Total current liabilities | $6.64M | $5.2M | $10.6M | $7.71M | $8.5M |
| Long-term debt | $0.00 | $0.00 | $170K | $340K | $490K |
| Deferred revenue, non-current | $18.7M | $18.7M | $18.7M | $18.7M | $0.00 |
| Total non-current liabilities | $18.8M | $18.8M | $19M | $19.7M | $1.75M |
| Capital lease obligations | $0.00 | $170K | $340K | $490K | $680K |
| Total liabilities | $25.5M | $24M | $29.6M | $27.4M | $10.3M |
| Common stock | $40K | $30K | $30K | $30K | $900K |
| Retained earnings | -$-326.69M | -$-299.72M | -$-281.04M | -$-265.52M | -$-248.83M |
| Accumulated other comprehensive income (loss) | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total equity | $64.4M | $14.3M | -$-18.55M | $5.84M | $15.2M |
| Total investments | $0.00 | $0.00 | $0.00 | $5.59M | $9.17M |
| Total debt | $0.00 | $170K | $530K | $720K | $930K |
| Net debt | -$-88.93M | -$-36.58M | -$-8.92M | -$-11.41M | -$-12.48M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | -$-31.08M | -$-22.7M | -$-20.25M | -$-19.16M | -$-17.73M |
| Depreciation and amortization | $20K | $90K | $90K | $90K | $90K |
| Stock-based compensation | $3.77M | $2.76M | $1.58M | $0.00 | $2.36M |
| Change in working capital | $1.89M | -$-5.44M | $4.39M | $5.38M | $40K |
| Accounts receivable | $0.00 | $40K | $70K | -$-120K | $100K |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 | -$-890K |
| Accounts payable | $1.53M | $0.00 | $2.93M | -$-860K | $1.83M |
| Net cash provided by operating activities | -$-25.25M | -$-25.31M | -$-19.08M | -$-15.25M | -$-19.31M |
| Investments in property, plant and equipment | $0.00 | $0.00 | $0.00 | -$-20K | $0.00 |
| Acquisitions, net | $0.00 | $0.00 | $4.4M | $0.00 | $0.00 |
| Net cash used for investing activities | $0.00 | $0.00 | $4.4M | -$-20K | $0.00 |
| Common stock issued | $77.5M | $52.8M | $12M | $14.8M | $26.8M |
| Common stock repurchased | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | $77.4M | $52.6M | $12M | $14M | $27M |
| Net change in cash | $52.2M | $27.3M | -$-2.68M | -$-1.29M | $7.67M |
| Cash at end of period | $88.9M | $36.8M | $9.45M | $12.1M | $13.4M |
| Operating cash flow | -$-25.25M | -$-25.31M | -$-19.08M | -$-15.25M | -$-19.31M |
| Capital expenditure | $0.00 | $0.00 | $0.00 | -$-20K | $0.00 |
| Free cash flow | -$-25.25M | -$-25.31M | -$-19.08M | -$-15.27M | -$-19.31M |
Line items
Line items
Line items
About vTv Therapeutics Inc.
vTv Therapeutics Inc. is a biopharmaceutical company in the clinical development stage, primarily focused on creating orally administered treatments, with a significant emphasis on diabetes. Its pipeline features lead candidates such as TTP399, an oral, small-molecule, liver-specific glucokinase activator targeting Type 1 diabetes. Another key investigational drug is HPP737, an oral phosphodiesterase type 4 (PDE4) inhibitor that does not cross the blood-brain barrier (non-CNS penetrant), designed to treat inflammatory conditions and psoriasis. Beyond these, vTv Therapeutics' broader clinical portfolio includes: TTP273, an oral small-molecule GLP-1 receptor agonist addressing postprandial glucose excursions in cystic fibrosis-related diabetes. HPP3033, which employs a non-electrophilic strategy to activate the Nrf2 pathway for chronic conditions linked to oxidative stress. Azeliragon, a RAGE antagonist being evaluated for inflammatory lung disorders, notably severe COVID-19, alongside pancreatic and breast cancers. HPP971, an Nrf2 activator aimed at renal diseases, developed in collaboration with pharmaceutical partners. Furthermore, vTv holds a licensing agreement with Reneo Pharmaceuticals, Inc. for the development and commercialization of its peroxisome proliferation-activated receptor delta agonist program, which features the compound HPP593. The company has also established various other licensing and research collaborations with entities such as Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., Newsoara Biopharma Co., Ltd., JDRF International, and Novo Nordisk A/S. Established in 2015, vTv Therapeutics is headquartered in High Point, North Carolina, and operates as a subsidiary of MacAndrews & Forbes Incorporated.
- CEO
- Paul J. Sekhri
- Employees
- 26
- Beta
- 0.29
Explore
Frequently asked questions
What is the intrinsic value of vTv Therapeutics Inc. (VTVT)?
InvestorsCraft does not currently publish an intrinsic value for VTVT. How the IC value is calculated.
Is VTVT undervalued?
InvestorsCraft does not publish an undervaluation signal for VTVT at this time.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.